A growing body of studies have shown that targeting IL-1β, a downstream cytokine activated by inflammasomes, using neutralizing antibodies is effective in ameliorating colonic inflammation in both animal models of colitis and IBD patients (8), whereas the high cost of antibody based therapy may limit its application (9). This evidence concerns the gene IL1B and inflammatory bowel disease.